⚠️ Notice: A scam is impersonating Endios Bio using a lookalike domain (endiosbio .us). We are not currently hiring — see our Careers page for details.

⚠️ Beware of job scams impersonating Endios Bio. Learn more →

Breakthrough Discoveries.
Breakthrough Discoveries.

Pioneering ALS therapeutics.

Pioneering ALS therapeutics.

Pioneering first-in-class treatments targeting PEG10, a newly discovered driver of ALS and neurodevelopmental disorders.

Pioneering first-in-class treatments targeting PEG10, a newly discovered driver of ALS and neurodevelopmental disorders.

Learn More

Learn More

Join Our Mailing List

Join Our Mailing List

Innovative Solutions for ALS and Rare Neurological Disorders

Innovative Solutions for ALS and Rare Neurological Disorders

About Us

Endios Bio develops novel therapeutics for ALS and rare neurological diseases based on breakthrough discoveries from Harvard Medical School and the University of Colorado Boulder (CU Boulder).

Endios Bio develops novel therapeutics for ALS and rare neurological diseases based on breakthrough discoveries from Harvard Medical School and the University of Colorado Boulder (CU Boulder).

Founded through CU Boulder’s Embark Deep Tech Startup Creator, we translate pioneering molecular biology into real-world therapeutics. We are targeting unexplored disease mechanisms to bring new hope to patients with limited treatment options.

Founded through CU Boulder’s Embark Deep Tech Startup Creator, we translate pioneering molecular biology into real-world therapeutics. We are targeting unexplored disease mechanisms to bring new hope to patients with limited treatment options.

Our Science
Our Science

Endios Bio Identifies PEG10 as New ALS Player

Our therapeutics are backed by published science.

Drives Early ALS Progression

PEG10 is an upstream factor in ALS, triggering early molecular changes that drive disease progression.

Drives Early ALS Progression

PEG10 is an upstream factor in ALS, triggering early molecular changes that drive disease progression.

Drives Early ALS Progression

PEG10 is an upstream factor in ALS, triggering early molecular changes that drive disease progression.

Abundant in ALS Spinal Tissue

PEG10 is dramatically accumulated in ALS spinal cords, compared to more than 7,000 proteins.

Abundant in ALS Spinal Tissue

PEG10 is dramatically accumulated in ALS spinal cords, compared to more than 7,000 proteins.

Abundant in ALS Spinal Tissue

PEG10 is dramatically accumulated in ALS spinal cords, compared to more than 7,000 proteins.

Disrupts Gene Expression Pathways

PEG10 self-cleaves into toxic particles—altering gene expression and contributing to neurodegeneration.

Disrupts Gene Expression Pathways

PEG10 self-cleaves into toxic particles—altering gene expression and contributing to neurodegeneration.

Disrupts Gene Expression Pathways

PEG10 self-cleaves into toxic particles—altering gene expression and contributing to neurodegeneration.

closeup of scientists hands filling viles

Media Highlights

Embark Showcase 2025: Featuring Endios Bio's Wendy Overton and PI Alexandra Whiteley
CU Venture Partners Showcase
The Scientist: An Ancient Viral Protein May Play a Key Role in ALS

Explore News & Press

  • Ascent Logo
  • Embark Logo
  • CU Venture Partners logo
  • Innosphere Ventures logo
closeup of scientists hands filling viles

Media Highlights

Embark Showcase 2025: Featuring Endios Bio's Wendy Overton and PI Alexandra Whiteley
CU Venture Partners Showcase
The Scientist: An Ancient Viral Protein May Play a Key Role in ALS

Explore News & Press

  • Ascent Logo
  • Embark Logo
  • CU Venture Partners logo
  • Innosphere Ventures logo
Therapeutic Pipeline

Therapeutic Approach

Our dual approach addresses both production and toxicity, opening multiple therapeutic paths for treating ALS and related conditions.

Endios Bio is developing two patented therapeutic programs aimed at neutralizing PEG10:

DNA Strands

dna strands

Blocks PEG10 translation at the RNA level—halting its production and impact.

small molecules

Targets PEG10’s toxic activity by preventing self-cleavage and disease progression.

Stay Connected

Join our Newsletter

Get scientific updates, company news, and therapeutic progress delivered to your inbox. Subscribe to the Endios Bio newsletter.